​

Dynavax (DVAX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

DVAX Stock Forecast

Dynavax (DVAX) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $31.00, with a high of $31.00 and a low of $31.00. This represents a 198.08% increase from the last price of $10.40.

$10 $15 $20 $25 $30 $35 High: $31 Avg: $31 Low: $31 Last Closed Price: $10.4

DVAX Stock Rating

Dynavax stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (90.00%), 0 Hold (0.00%), 1 Sell (10.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 1 0 9 Strong Sell Sell Hold Buy Strong Buy

DVAX Price Target Upside V Benchmarks

TypeNameUpside
StockDynavax198.08%
SectorHealthcare Stocks 24.81%
IndustrySpecialty & Generic Drug Manufacturers Stocks29.65%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$31.00$30.00
Last Closing Price$10.40$10.40$10.40
Upside/Downside-198.08%188.46%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2512--14
May, 2512--14
Apr, 2512--14
Mar, 2512--14
Feb, 25221--5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 07, 2025Jason ButlerJMP Securities$31.00$10.92183.88%198.08%
Jun 28, 2024Edward WhiteH.C. Wainwright$29.00$11.37155.06%178.85%
May 14, 2024Paul ChoiGoldman Sachs$20.00$11.0081.82%92.31%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 07, 2025CitigroupOutperformOutperformhold
Jan 14, 2025H.C. WainwrightBuyBuyhold
Oct 15, 2024H.C. WainwrightBuyBuyhold
Jun 28, 2024H.C. WainwrightBuyBuyhold
May 14, 2024Goldman SachsNeutralNeutralhold
May 14, 2024H.C. WainwrightBuyBuyhold
Feb 24, 2023JMP SecuritiesMarket OutperformMarket Outperformhold
Sep 27, 2022JMP SecuritiesOutperforminitialise

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.91$0.62$2.32$-0.05$0.21----
Avg Forecast$-0.87$0.45$1.91$-0.13$0.20$0.27$0.51$0.71$1.00
High Forecast$-0.83$0.48$1.96$-0.04$0.25$0.29$0.57$0.75$1.02
Low Forecast$-0.92$0.43$1.86$-0.31$0.16$0.23$0.47$0.64$0.98
Surprise %4.60%37.78%21.47%-61.54%5.00%----

Revenue Forecast

$0 $150M $300M $450M $600M $750M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$46.55M$439.44M$722.68M$232.28M$277.25M----
Avg Forecast$40.06M$449.44M$717.80M$229.42M$278.12M$333.51M$386.49M$464.32M$585.00M
High Forecast$41.82M$469.13M$733.21M$231.54M$278.23M$333.54M$386.49M$464.32M$595.70M
Low Forecast$38.80M$435.23M$704.07M$227.30M$278.00M$333.47M$386.49M$464.32M$575.93M
Surprise %16.19%-2.22%0.68%1.25%-0.31%----

Net Income Forecast

$-100M $10M $120M $230M $340M $450M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-91.78M$76.71M$293.16M$-6.39M$27.31M----
Avg Forecast$-64.66M$103.14M$343.48M$-6.39M$26.91M$33.57M$70.07M$89.56M$128.77M
High Forecast$-48.24M$132.86M$422.19M$-4.92M$32.81M$37.91M$73.69M$96.65M$131.83M
Low Forecast$-81.08M$73.41M$264.78M$-7.86M$21.00M$29.24M$60.30M$82.47M$126.18M
Surprise %41.93%-25.62%-14.65%-1.50%----

DVAX Forecast FAQ

Is Dynavax stock a buy?

Dynavax stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 0 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Dynavax is a favorable investment for most analysts.

What is Dynavax's price target?

Dynavax's price target, set by 10 Wall Street analysts, averages $31 over the next 12 months. The price target range spans from $31 at the low end to $31 at the high end, suggesting a potential 198.08% change from the previous closing price of $10.4.

How does Dynavax stock forecast compare to its benchmarks?

Dynavax's stock forecast shows a 198.08% upside, outperforming the average forecast for the healthcare stocks sector (24.81%) and outperforming the specialty & generic drug manufacturers stocks industry (29.65%).

What is the breakdown of analyst ratings for Dynavax over the past three months?

  • June 2025: 25.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 25.00% Strong Sell.
  • May 2025: 25.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 25.00% Strong Sell.
  • April 2025: 25.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 25.00% Strong Sell.

What is Dynavax’s EPS forecast?

Dynavax's average annual EPS forecast for its fiscal year ending in December 2025 is $0.27, marking a 28.57% increase from the reported $0.21 in 2024. Estimates for the following years are $0.51 in 2026, $0.71 in 2027, and $1 in 2028.

What is Dynavax’s revenue forecast?

Dynavax's average annual revenue forecast for its fiscal year ending in December 2025 is $333.51M, reflecting a 20.29% increase from the reported $277.25M in 2024. The forecast for 2026 is $386.49M, followed by $464.32M for 2027, and $585M for 2028.

What is Dynavax’s net income forecast?

Dynavax's net income forecast for the fiscal year ending in December 2025 stands at $33.57M, representing an 22.94% increase from the reported $27.31M in 2024. Projections indicate $70.07M in 2026, $89.56M in 2027, and $128.77M in 2028.